CA2327585A1 - Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation - Google Patents

Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation Download PDF

Info

Publication number
CA2327585A1
CA2327585A1 CA002327585A CA2327585A CA2327585A1 CA 2327585 A1 CA2327585 A1 CA 2327585A1 CA 002327585 A CA002327585 A CA 002327585A CA 2327585 A CA2327585 A CA 2327585A CA 2327585 A1 CA2327585 A1 CA 2327585A1
Authority
CA
Canada
Prior art keywords
phenyl
trifluoromethyl
methylsulfonyl
fluorophenyl
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002327585A
Other languages
English (en)
French (fr)
Inventor
Susan Boyce
Raymond George Hill
Nadia Melanie Rupniak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2327585A1 publication Critical patent/CA2327585A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002327585A 1998-05-21 1999-05-19 Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation Abandoned CA2327585A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9810920.0A GB9810920D0 (en) 1998-05-21 1998-05-21 Therapeutic use
GB9810920.0 1998-05-21
PCT/GB1999/001632 WO1999059635A1 (en) 1998-05-21 1999-05-19 Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation

Publications (1)

Publication Number Publication Date
CA2327585A1 true CA2327585A1 (en) 1999-11-25

Family

ID=10832454

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002327585A Abandoned CA2327585A1 (en) 1998-05-21 1999-05-19 Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation

Country Status (6)

Country Link
EP (1) EP1079863A1 (ja)
JP (1) JP2002515461A (ja)
AU (1) AU758983B2 (ja)
CA (1) CA2327585A1 (ja)
GB (1) GB9810920D0 (ja)
WO (1) WO1999059635A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
KR20040072004A (ko) 2003-02-07 2004-08-16 삼성에스디아이 주식회사 유기 전계 발광 소자용 발광 화합물 및 그를 이용한 유기전계발광 소자
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
WO2006081088A2 (en) * 2005-01-24 2006-08-03 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an nsaid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
GB2287404A (en) * 1994-03-15 1995-09-20 Pfizer Antiinflammatory and analgesic compositions
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
GB9426103D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
KR19980703559A (ko) * 1995-04-04 1998-11-05 그레이엄브레레톤 이미다조[1,2-a]피리딘 유도체
WO1997025988A1 (en) * 1996-01-17 1997-07-24 Eli Lilly And Company Methods of treating or preventing pain or nociception
CN1205193C (zh) * 1996-08-14 2005-06-08 G·D·瑟尔公司 4-[5-甲基-3-苯基异噁唑-4-基]苯磺酰胺的晶型
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists

Also Published As

Publication number Publication date
GB9810920D0 (en) 1998-07-22
AU758983B2 (en) 2003-04-03
JP2002515461A (ja) 2002-05-28
EP1079863A1 (en) 2001-03-07
WO1999059635A1 (en) 1999-11-25
AU3948699A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
US6232315B1 (en) Method for treating inflammatory diseases by administering a thrombin inhibitor
US6245797B1 (en) Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6136804A (en) Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
SK13952002A3 (sk) Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén
EP1058559B1 (en) Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor
KR20060125763A (ko) 통증의 치료, 변형 및 관리를 위한 선택적인 사이토킨 억제약물을 포함하는 조성물 및 이의 사용 방법
JP2012255039A (ja) ニコチン性アセチルコリンα7受容体アゴニストの組合せ剤
PT1536782E (pt) Combinação sinérgica de um ligando alfa-2-delta e um inibidor pdev para ser utilizada no tratamento da dor
AU2003284979B2 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
AU753657B2 (en) Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease
US20020016342A1 (en) Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor
CA2327585A1 (en) Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation
KR20050057672A (ko) 통증의 치료, 변형 및 관리를 위한 면역조절 화합물을포함하는 조성물 및 이의 사용 방법
US20040097573A1 (en) Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
GB2318293A (en) Use of a tachykinin antagonist and rizatriptan against migraine
ZA200207701B (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug.
JP2005532322A (ja) オピオイド鎮痛薬とnsaidの相乗的な組合せ

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead